| Internet Addiction in adolescence: Neurobiological, psychosocial and clinical issues L Cerniglia, F Zoratto, S Cimino, G Laviola, M Ammaniti, W Adriani Neuroscience & Biobehavioral Reviews 76, 174-184, 2017 | 422 | 2017 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 335 | 2019 |
| Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer M Schirripa, C Cremolini, F Loupakis, M Morvillo, F Bergamo, F Zoratto, ... International journal of cancer 136 (1), 83-90, 2015 | 171 | 2015 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 160 | 2020 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 153 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 137 | 2019 |
| Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis F Zoratto, L Rossi, M Verrico, A Papa, E Basso, A Zullo, L Tomao, A Romiti, ... Tumor Biology 35, 6195-6206, 2014 | 137 | 2014 |
| Positron Emission Tomography (PET) radiotracers in oncology–utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC) E Miele, GP Spinelli, F Tomao, A Zullo, F De Marinis, G Pasciuti, L Rossi, ... Journal of Experimental & Clinical Cancer Research 27, 1-10, 2008 | 137 | 2008 |
| Current approach in the treatment of hepatocellular carcinoma L Rossi, F Zoratto, A Papa, F Iodice, M Minozzi, L Frati, S Tomao World journal of gastrointestinal oncology 2 (9), 348, 2010 | 126 | 2010 |
| Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective … DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ... The Lancet Oncology 22 (12), 1669-1680, 2021 | 112 | 2021 |
| Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer F Graziano, A Ruzzo, E Giacomini, T Ricciardi, G Aprile, F Loupakis, ... The pharmacogenomics journal 17 (3), 258-264, 2017 | 108 | 2017 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 95 | 2021 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 95 | 2020 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 85 | 2021 |
| Angiogenesis and antiangiogenic agents in cervical cancer F Tomao, A Papa, L Rossi, E Zaccarelli, D Caruso, F Zoratto, ... OncoTargets and therapy, 2237-2248, 2014 | 82 | 2014 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Compromised decision-making and increased gambling proneness following dietary serotonin depletion in rats S Koot, F Zoratto, T Cassano, R Colangeli, G Laviola, R Van Den Bos, ... Neuropharmacology 62 (4), 1640-1650, 2012 | 74 | 2012 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 69 | 2020 |
| Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid registry DJ Pinato, M Patel, L Scotti, E Colomba, S Dolly, A Loizidou, J Chester, ... JAMA oncology 8 (1), 114-122, 2022 | 65 | 2022 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 61 | 2020 |
